Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ejogrb.2019.02.029 | DOI Listing |
Clin Epigenetics
December 2024
Hereditary Cancer Group, ONCOBELL Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
Background: Lynch syndrome (LS), characterised by an increased risk for cancer, is mainly caused by germline pathogenic variants affecting a mismatch repair gene (MLH1, MSH2, MSH6, PMS2). Occasionally, LS may be caused by constitutional MLH1 epimutation (CME) characterised by soma-wide methylation of one allele of the MLH1 promoter. Most of these are "primary" epimutations, arising de novo without any apparent underlying cis-genetic cause, and are reversible between generations.
View Article and Find Full Text PDFCancers (Basel)
October 2024
Department of Medical Research, Taichung Veterans General Hospital, Taichung 40705, Taiwan.
Lynch syndrome (LS) is an autosomal dominant disorder characterized by increased risks of colorectal and endometrial cancers. LS is defined by pathogenic variants in mismatch repair (MMR) genes, including MLH1, MSH2, and MSH6. Data on the prevalence and associated cancer risks of LS in the Han Chinese population remain limited.
View Article and Find Full Text PDFJ Hypertens
October 2024
NHC Key Laboratory of Endocrinology, Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences.
J Cutan Pathol
December 2024
Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands.
J Allergy Clin Immunol Glob
November 2024
Department of Clinical Immunology, Kochi Medical School, Kochi University, Nankoku, Japan.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!